Dressings and topical agents for arterial leg ulcers

Dressings and topical agents for arterial leg ulcers

BACKGROUND

It is estimated that up to 1% of people in high-income countries suffer from a leg ulcer at some time in their life. The majority of leg ulcers are associated with circulation problems; poor blood return in the veins causes venous ulcers (around 70% of ulcers) and poor blood supply to the legs causes arterial ulcers (around 22% of ulcers). Treatment of arterial leg ulcers is directed towards correcting poor arterial blood supply, for example by correcting arterial blockages (either surgically or pharmaceutically). If the blood supply has been restored, these arterial ulcers can heal following principles of good wound-care. Dressings and topical agents make up a part of good wound-care for arterial ulcers, but there are many products available, and it is unclear what impact these have on ulcer healing. This is the third update of a review first published in 2003.

OBJECTIVES

To determine whether topical agents and wound dressings affect healing in arterial ulcers. To compare healing rates and patient-centred outcomes between wound dressings and topical agents.

SEARCH METHODS

The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature and Allied and Complementary Medicine databases, the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials register to 28 January 2019.

SELECTION CRITERIA

Randomised controlled trials (RCTs), or controlled clinical trials (CCTs) evaluating dressings and topical agents in the treatment of arterial leg ulcers were eligible for inclusion. We included participants with arterial leg ulcers irrespective of method of diagnosis. Trials that included participants with mixed arterio-venous disease and diabetes were eligible for inclusion if they presented results separately for the different groups. All wound dressings and topical agents were eligible for inclusion in this review. We excluded trials which did not report on at least one of the primary outcomes (time to healing, proportion completely healed, or change in ulcer area).

DATA COLLECTION AND ANALYSIS

Two review authors independently extracted information on the participants' characteristics, the interventions, and outcomes using a standardised data extraction form. Review authors resolved any disagreements through discussion. We presented the data narratively due to differences in the included trials. We used GRADE to assess the certainty of the evidence.

MAIN RESULTS

Two trials met the inclusion criteria. One compared 2% ketanserin ointment in polyethylene glycol (PEG) with PEG alone, used twice a day by 40 participants with arterial leg ulcers, for eight weeks or until healing, whichever was sooner. One compared topical application of blood-derived concentrated growth factor (CGF) with standard dressing (polyurethane film or foam); both applied weekly for six weeks by 61 participants with non-healing ulcers (venous, diabetic arterial, neuropathic, traumatic, or vasculitic). Both trials were small, reported results inadequately, and were of low methodological quality. Short follow-up times (six and eight weeks) meant it would be difficult to capture sufficient healing events to allow us to make comparisons between treatments. One trial demonstrated accelerated wound healing in the ketanserin group compared with the control group. In the trial that compared CGF with standard dressings, the number of participants with diabetic arterial ulcers were only reported in the CGF group (9/31), and the number of participants with diabetic arterial ulcers and their data were not reported separately for the standard dressing group. In the CGF group, 66.6% (6/9) of diabetic arterial ulcers showed more than a 50% decrease in ulcer size compared to 6.7% (2/30) of non-healing ulcers treated with standard dressing. We assessed this as very-low certainty evidence due to the small number of studies and arterial ulcer participants, inadequate reporting of methodology and data, and short follow-up period. Only one trial reported side effects (complications), stating that no participant experienced these during follow-up (six weeks, low-certainty evidence). It should also be noted that ketanserin is not licensed in all countries for use in humans. Neither study reported time to ulcer healing, patient satisfaction or quality of life.

AUTHORS' CONCLUSIONS

There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers.

Dressings and topical agents for arterial leg ulcers

BACKGROUND

It is estimated that people in industrialised countries have a 1% chance of suffering from a leg ulcer at some time in their life. The majority of leg ulcers are associated with circulation problems; poor blood return in the veins causes venous ulcers (around 70% of ulcers) and poor blood supply to the legs causes arterial ulcers (around 22% of ulcers). Treatment of arterial leg ulcers is directed towards correcting the poor arterial blood supply, for example by correcting arterial blockages (either surgically or pharmaceutically). If the blood supply has been restored, these arterial ulcers can heal following principles of good wound care. Dressings and topical agents make up a part of good wound care for arterial ulcers but there are many products available and it is unclear what impact these have on ulcer healing. This is an update of a review first published in 2003.

OBJECTIVES

To determine whether topical agents and wound dressings affect healing in arterial ulcers. To compare healing rates, patient-centred outcomes and costs between wound dressings and topical agents.

SEARCH METHODS

For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched November 2014) and The Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library) (2014, Issue 10).

SELECTION CRITERIA

Randomised controlled trials (RCTs), or controlled clinical trials (CCTs) evaluating dressings and topical agents in the treatment of arterial leg ulcers were eligible for inclusion. The participants had to have ulcers that were described as arterial, and the time to healing, proportion completely healed, or rate of reduction in ulcer area had to be reported. All wound dressings and topical agents were eligible for inclusion in this review.

DATA COLLECTION AND ANALYSIS

The two review authors independently extracted information on the participants' characteristics, the interventions, and outcomes using a standardised data extraction form. Disagreements between the review authors were resolved through discussion.

MAIN RESULTS

One trial met the inclusion criteria, which was a small trial that compared 2% ketanserin ointment in polyethylene glycol (PEG) with vehicle alone (PEG) control, changed twice a day in 40 participants with arterial leg ulcers. The overall quality of the evidence was low with a single small included study which showed inadequate reporting of the results and had too short a follow-up time (eight weeks) to be able to capture sufficient healing events to allow comparisons to be made. In addition, the study was of low methodological quality. The majority of the 'risk of bias' domains received an 'unclear' risk rating as very little information was provided in the text on the methods of the study. The trial demonstrated increased wound healing in the ketanserin group, compared with the control group, but the trial was too small and had too short a follow-up period (eight weeks) to be able to determine whether there was any difference in healing rates. It should also be noted that ketanserin is not licensed in all countries for use in humans.

AUTHORS' CONCLUSIONS

There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers.

Understanding overgranulation in tissue viability practice

Overgranulation is a difficult condition to deal with and is thought to be due to possible infection or to use of occlusive dressings. The overgranulating tissue can be soft and oedematous with a shiny appearance. The fastest route to treatment (steroids or silver nitrate) may be aggressive and should be used sparingly (if at all). This article provides an outline of the process or tissue overgranulation in wounds and its appropriate clinical management.

Preferences of patients, doctors, and nurses regarding wound dressing characteristics: A conjoint analysis

The different choices doctors, nurses, and patients make regarding wound dressing materials are generally based on personal preferences, because strong evidence and guidelines on local wound care for open wounds are lacking. We studied which attributes of a wound dressing doctors, nurses, and patients consider the most important. A conjoint analysis questionnaire comprising paper-based descriptions with six attributes, and questions regarding the willingness-to-pay for these attributes were sent out to surgical patients, (assistant)-surgeons and nurses. Preferences for wound dressing attributes were similar for doctors (n=50), nurses (n=150), and patients (n=74). Pain during dressing changes, duration of hospitalization, and wound healing time were ranked highest. Doctors would spend more money on a shorter hospitalization, nurses on pain reduction, and patients on quicker wound healing. Patients were willing to pay a relatively small monthly amount out of pocket for a dressing that would result in a quicker and less-painful wound healing. Doctors, nurses, and patients prefer similar attributes of wound dressing materials, but differ in their willingness-to-pay. To achieve a more consistent local wound care, clinical decision-making should be in accordance with these preferences. These should also be the focus for manufacturers and researchers to obtain more evidence on which materials best match these attributes.

Silver dressings: their role in wound management

Dressings have a part to play in the management of wounds; whether they are sutured or open, usually chronic wounds of many aetiologies which are healing by secondary intention. They traditionally provide a moist wound environment, but this property has been extended through simple to complex, active dressings which can handle excessive exudate, aid in debridement, and promote disorganised, stalled healing. The control of infection remains a major challenge. Inappropriate antibiotic use risks allergy, toxicity and most importantly resistance, which is much reduced by the use of topical antiseptics (such as povidone iodine and chlorhexidine). The definition of what is an antimicrobial and the recognition of infection has proven difficult. Although silver has been recognised for centuries to inhibit infection its use in wound care is relatively recent. Evidence of the efficacy of the growing number of silver dressings in clinical trials, judged by the criteria of the Cochrane Collaboration, is lacking, but there are good indications for the use of silver dressings, to remove or reduce an increasing bioburden in burns and open wounds healing by secondary intention, or to act as a barrier against cross contamination of resistant organisms such as MRSA. More laboratory, and clinical data in particular, are needed to prove the value of the many silver dressings which are now available. Some confusion persists over the measurement of toxicity and antibacterial activity but all dressings provide an antibacterial action, involving several methods of delivery. Nanocrystalline technology appears to give the highest, sustained release of silver to a wound without clear risk of toxicity.

Dressings and topical agents for arterial leg ulcers

BACKGROUND

It is estimated that people in industrialised countries have a 1% chance of suffering from a leg ulcer at some time in their life. The majority of leg ulcers are associated with circulation problems; poor blood return in the veins causes venous ulcers (around 70% of ulcers) and poor blood supply to the legs causes arterial ulcers (around 25% of ulcers). Treatment of arterial leg ulcers is directed towards correcting the poor arterial blood supply, for example, by surgically correcting arterial blockages, and by supporting ulcer healing using topical agents (medicines in cream/ointment) and wound dressings. There are a large number of topical agents and wound dressings available and it is unclear what impact these have on ulcer healing.

OBJECTIVES

To determine whether topical agents and wound dressings affect the rate of healing in arterial ulcers. To compare healing rates, costs and patient-centred outcomes between wound dressings and topical agents.

SEARCH STRATEGY

Potential trials were sought through the Specialised Trials Registers of the Cochrane Wounds Group (last searched April 2002), the Cochrane Peripheral Vascular Diseases Group (last searched November 2006) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Issue 4, 2006

SELECTION CRITERIA

Randomised controlled trials (RCTs), or controlled clinical trials (CCTs) of dressings and topical agents for arterial leg ulcers were eligible for inclusion. The participants had to have ulcers that were described as arterial, and the time to healing, proportion completely healed, or rate of reduction in ulcer area had to be reported. All wound dressings and topical agents were eligible for inclusion in this review.

DATA COLLECTION AND ANALYSIS

Information on the participants' characteristics, the interventions, and outcomes, as well as data on the trial methods, such as blinding of patients and clinicians, and allocation concealment were extracted using a standardised data extraction form.

MAIN RESULTS

One trial met the inclusion criteria. This small trial compared ketanserin ointment with vehicle alone, changed twice a day. The trial was too small and for too short a follow-up period to be able to determine whether there was any difference in healing rates.

AUTHORS' CONCLUSIONS

There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers. Inadequate description of the people in the one included trial means that the results cannot be easily applied to other clinical populations.

Systematic review of dressings and topical agents for surgical wounds healing by secondary intention

Background

The best dressing for postoperative wounds healing by secondary intention is unknown.

Methods

A systematic review was conducted to assess the effectiveness of dressings and topical agents on such wounds. Main endpoints were wound healing, pain, patient satisfaction, costs and hospital stay. Systematic methodological appraisal and data extraction were performed by independent reviewers.

Results

Fourteen reports of 13 randomized clinical trials on dressings or topical agents (gauze, foam, bead, alginate and hydrocolloid dressing) for postoperative wounds healing by secondary intention were identified; they were of weak methodological quality. In general, no statistically significant differences in wound healing were found for various dressing comparisons (11 of 13 trials). Patients experienced significantly more pain (four of six trials) and were less satisfied when gauze was used (three of six trials). Gauze was inexpensive, but its use was associated with significantly more nursing time than dressing with foam (two of three trials). No substantial differences in hospital stay were found (four of five trials).

Conclusions

Only small, poor-quality trials exist, rendering the evidence insufficient. Foam is best studied as an alternative to gauze and appears to be preferable in terms of pain reduction, patient satisfaction and nursing time.

Evaluation study of the properties of two adhesive foam dressings

The primary objective of this study was to assess the skin stripping of wounds (defined as periwound skin blistering; Fowler, 1990) when treated with an adhesive hydrocellular foam dressing (Allevyn trade mark Adhesive, Smith and Nephew) and a self-adherent soft silicone foam dressing (Mepilex trade mark Border, MöInlycke Health Care). The secondary objectives were to assess wound healing, wound appearance and pain. Data were collected over one year from 403 wounds in 206 patients treated in nursing homes. At follow-up assessment, there was some evidence of skin stripping with both products - 5% (5/106) with the adhesive hydrocellular, and 4% (4/100 with the self-adherent dressing. The results of the study reveal that the closure rates achieved with the two dressings were similar, and that both dressings were equally safe in terms of skin stripping. Independent nurse evaluations highlighted the failure of the self-adherent soft silicone foam dressing to either initially adhere to the wound area, or to remain in contact for more than a few days, and frequently needed the application of additional tape to ensure adhesion. The failure of the self-adhesive soft silicone foam dressing to adhere to the periwound area was a significant deterrent to staff to use this type of dressing routinely.